Updated data on the first 134 chronic lymphocytic leukemia patients treated with single-agent acalabrutinib shows that the drug was well-tolerated in the majority of patients treated and responses were durable over time, ...
Dec 13, 2017
0
3
Research results highlighted today at the press conference of a major medical meeting report no benefit from the use of either Sutent (sunitinib) or Nexavar (sorafenib) among patients with locally advanced renal cell carcinoma ...
Feb 24, 2015
0
9
Patients whose lung cancer has developed resistance to the drug gefitinib experience no statistically significant improvement in progression-free survival from continued treatment with the drug in addition to chemotherapy, ...
Sep 29, 2014
0
0
Due to their rapid metastatic spread, pancreatic tumors are among the most aggressive types of cancer. Only three to five percent of patients have a survival rate of five years. A team of KIT researchers has now established ...
Nov 10, 2015
0
4
Atherosclerosis is a leading cause of heart attacks and stroke. The narrowing of blood vessels that is caused by atherosclerosis can be treated with angioplasty or stenting to improve blood flow. However, the stenting process ...
Nov 17, 2014
0
0
A high-risk subtype of acute lymphoblastic leukemia (ALL) first identified in children is highly prevalent in adults with ALL and is associated with a poor outcome, according to an international collaboration led by St. Jude ...
Nov 21, 2016
0
0
Tyrosine kinase inhibitors (TKIs) may improve treatment outcome for children and young adults with Ph-like acute lymphoblastic leukemia (Ph-like ALL), a disease with dismal prognosis, according to data presented at the American ...
Sep 23, 2014
0
0
How is drug resistance of cancer cells affected by ABC-transporters? A new research paper, published in the open access journal BioDiscovery, looks at the complex relationship between the second generation of tyrosine kinase ...
Mar 8, 2017
0
0
Researchers at Moffitt Cancer Center have determined that chronic myeloid leukemia patients who are treated with a class of oral chemotherapy drugs known as a tyrosine kinase inhibitors have significant side effects and quality-of-life ...
Jun 10, 2013
0
0
Tumor-initiating cells, or cancer stem cells, are gaining attention in cancer therapy, as they can travel through the body and cause cancerous tumors at other sites through metastasis. These cells also may cause resistance ...
Jul 5, 2023
0
0
